UBS lowered the firm’s price target on DexCom (DXCM) to $95 from $106 and keeps a Buy rating on the shares. DexCom’s solid sales beat overshadowed by margin weakness, but the firm remains confident in a sustainable mid-to-high teens sales growth outlook, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM: